High Blood Pressure Research Council of Australia


HBPRCA Email Newsletter

October 2009


Welcome Note from Geoff Head

Welcome to the October e-news, which is an important one as it’s the last before we meet in December. So a reminder to register now and book your accommodation. This issue we have a feature article from our colleagues in Milan on the long term risk of hypertension in white coat or masked hypertension.



ISH2012 – As you are all aware, the HBPRCA will be hosting ISH2012 in Sydney, 30 September – 3 October. As members of the HBPRCA, we would like you to advertise the Congress, by downloading the slides and including them at the end of your presentations. Please click here to download.


ISH2010 – will be in Vancouver on the 26th-30th September. PowerPoint slides for this meeting are available here.


President’s Message

2009 Annual Scientific Meeting News

2009 Workshop News

Student News

Membership News

Society Liaison News

Sponsor Profiles

Feature Article: Long-term risk of sustained hypertension in white-coat or masked hypertension

Ambulatory Blood Pressure Monitoring (ABPM) Working Group Initiative

Upcoming Meetings



President’s Message from Stephen Harrap

I have just returned form a very enjoyable and productive sabbatical period in Paris, where I worked in the College de France and at the Research Centre at the Georges Pompidou Hospital. For those of you old enough to take sabbatical and keep putting it off, don’t procrastinate. For those of you young enough to be taking a postdoc period overseas, go if you can. Apart from the fact that you broaden your research horizons and see things from a different perspective, you also create memories that will last a lifetime. Trust me you won’t regret the experience. The trick is to set up things well in advance and part of that process is meeting the people and visiting the labs where you might go. Much of this happens around conferences and your Council does the best it can to create opportunities to travel to such meetings, especially for our younger members.


This e-News contains many examples of that support including the recent first successful visit of our Young Investigator Michael De Silva to the High Blood Pressure Research Council of the American Heart Association as well as the new category of membership that allows young investigators to retain their HBPRCA membership at no cost while they are undertaking postdoc study abroad. These are 2 great new initiatives added to our existing BHS exchange arrangements.


Remember also that we have negotiated an exclusive agreement with the BHS that allows up to 10 of our members to register and attend their September meeting. In the light of the encouragement above, why not make the BHS part of your travel plans? The meeting is held usually in either Oxford or Cambridge and it is a high quality mix of clinical and basic science research. It makes a great base to tour European labs and with venues like St John’s College, Cambridge this year (see photos), who could ask for more?



St John’s College, Cambridge BHS September 2009


Presidential Friends, Stephen Harrap (HBPRCA) & Gordon McInnes (BHS), Cambridge September 2009


Finally, you can read something about the people behind our valued sponsors. This is a great opportunity to get to know them personally and for our younger members their stories provide insights into potential career directions.


Happy reading and see you all in Sydney in December.



2009 Annual Scientific Meeting News from Kate Denton and Markus Schlaich

IMPORTANT: Don’t forget that the meeting is being held from Tuesday 1st to Thursday 3rd December this year


The meeting is shaping up and it looks like it is going to be well attended. The abstracts are in and being ranked as we speak.  We have had an excellent turn out for the meeting in Sydney, with "115" abstracts submitted. Remember, our guest speakers are Dr Frans Leenen (RD Wright), Prof Michael Cowley (Austin Doyle) and Dr Alex Brown (Colin Johnston) and we can expect some interesting and thought provoking presentations.


You should also check out the "Environmentally Influenced Cardiovascular Disease: From the Fetus to the Adult" workshop program that has been finalised and it will have appeal to a wide audience and attendance is expected to be high.


Finally, we will be inviting ECR and students to again participate in judging the poster presentations.  Any members interested in acting as mentors in this endeavour should contact Erin O’Callaghan, our student member, who is helping to organise this event or myself.


Registration and abstract submissions are now officially open on-line and via paper form. For information on the meeting, please visit the website.


Register now!

1 – 3 December 2009
Luna Park Sydney


Close of EB registrations                 Friday 23 October 2009



Workshop News from Geoff Head

ASM Workshop Tuesday 1st December 2009: “Environmentally Influenced Cardiovascular Disease: From the Fetus to the Adult”

This workshop held over a single day will attempt to bring together various streams of research by scientists and clinicians involved in the environmental influences leading to cardiovascular disease. The plan is for sessions involving fetal programming, children's issues through to the adult with attention to special areas of concern such as indigenous Australians.


Session topics

Early Life Programming of Cardiovascular Disease

Adult Obesity and Cardiovascular Disease

Early Life Programming of Obesity

Implications for Clinical Management Strategies


We have 24 exciting speakers for our ASM workshop on Tuesday the 1st December including our international guest speaker Professor Kevin Grove who will discuss "The effects of fetal lipotoxicity on programming of the cardiovascular system in the nonhuman primate"



Crystal Palace, 1 Olympic Drive, Milsons Point, New South Wales


Registration fee 

$66.00, incl. GST (via the Meeting First website)


Workshop Dinner

Curve Restaurant, Vibe Hotel North Sydney ($55, incl. GST)


Workshop Committee: Geoff Head, Kate Denton, Markus Schlaich, Louise Burrell, James Armitage, Mary Wlodek, Bruce Neal and Annemarie Hennessy



Student News

Important message to all graduate students who are members of the HBPRCA ***IT’S FREE***

Are you a graduate student working in hypertension or a related field?


As the HBPRCA is affiliated with the International Society of Hypertension (ISH) there is an incredible opportunity for you to become


A Research Fellow of the International Society of Hypertension AT NO COST!


This permits you to

1.       Obtain copies of the quarterly Society Newsletter, Hypertension News

2.       Save on conference registration fees

3.       Enjoy broader opportunities to build relationships and network with peers and develop your career as a leader in your field

4.       Have access to the full ISH Membership List (over 800 members)

5.       Be eligible to receive or nominate candidates for the Biennial ISH Awards

6.       Be exempt from paying the annual ISH membership fee

7.       Be able to indicate your status as an ISH Research Fellow on your CV


Please make sure you checkout the fabulous new ISH website (http://www.ish-world.com/default.aspx?Graduate_Students).



Membership News from Doug McKitrick

Membership in the HBPRCA continues to grow. The June membership report tabled at the August 19 Executive Committee meeting indicated that there are 271 current members of the HBPRCA. By comparison, 5 years ago at the end of 2004, membership stood at 200.


During the August 19 teleconference the Executive also endorsed a new membership category intended to help our student members retain an affiliation with the HBPRCA and move from student to ordinary membership. This new category, called Special Circumstances Membership, is particularly aimed at students that have completed their degrees in Australia and have moved overseas for additional training. The description and conditions of Special Circumstances Membership are:


This membership category has been established for recent graduates moving from Student Membership to full Ordinary Membership in the HBPRCA.


In an instance where the Applicant has:

1.       completed a degree program and;

2.       is no longer considered eligible for Student Membership and;

3.       has requested a temporary exemption from paying membership fees


The HBPRCA Executive:

1.       with the recognition that the exemption allows the Applicant to retain an affiliation with the HBPRCA and;

2.       with the understanding that the Applicant will become a full Ordinary Member on return to Australia


may grant the exemption and grant the Applicant Special Circumstances Membership on the basis that the Applicant:

1.       is in the first 5 years after graduation from the degree program

2.       is engaged in relevant career training in a laboratory outside Australia


With Special Circumstances Membership the Applicant will be:

  1. entitled to receive HBPRCA E-News by email
  2. allowed to submit abstracts for the HBPRCA ASM during the period of Special Circumstances Membership 
  3. allowed to register as an Ordinary Member for the HBPRCA ASM during the period of Special Circumstances Membership



Society Liaison News from Bruce Neal

The United Kingdom

The British Hypertension Society has just held its Annual Meeting where we were ably represented by Stephen Harrap who kindly took a day or  two out of his sabbatical in Paris.  The overall winner of the British Young Investigator Prizes this year was Dr Mark Glover (pictured) from the Clinical Pharmacology Unit at Addenbrooke’s Hospital in Cambridge and he will be attending our meeting in December.  His presentation will be entitled ‘The thiazide-sensitive Na-Cl cotransporter in the distal nephron (NCCT) is regulated by both kinases and phosphatases.’   Mark is hoping to make visits to one or two laboratories working in his field during his visit to Australia so please do let us know if you would be interested in hosting him.  Other news from the UK is that Gordon McInnes has now stepped down as President with Professor Mark Caulfield moving into the role.  The next Annual Scientific Meeting of the British Hypertension Society will be held from 13th – 15th September 2010, at St. John’s College, Cambridge.  Once again, the British Hypertension Society is pleased to extend an invitation to members of the HBPRCA to submit abstracts and attend the 2010 meeting, and we will of course be sending a young investigator as before.



We have now made the second awards for the Franco-Australian Exchange travel grants.  The winner from the five applicants from the Australian side, Erin O’Callaghan, will be spending three months working with Genevieve Nguyen at the College de France Center for Interdisciplinary Research in Biology at INSERM.  Erin's work will seek to determine the distribution of the (pro) renin receptor in the cardiovascular centres of the rat brain.  In regard to our colleagues in France, we have recently heard form Prof Xavier Jeunemaitre, the incoming president of the French Society, that Pr Pathak Atul from Tolouse will be visiting Australia between June and September next year. Professor Gavin Lambert at the Baker Institute in Melbourne will be hosting.


The United States of America

Thanks primarily to the sterling efforts of Stephen and his counterpart in the US, Rhian Toyuz, we now have a new exchange program with the USA.  It has now been confirmed that a reciprocal arrangement with the US Council has been developed. The winner of the AHA Goldblatt prize will be given the opportunity to come to Australia, commencing at the 2010 ASM. From our side, Michael De Silva recently made the trip to the 63rd High Blood Pressure Research Conference in Chicago where he presented on "Defining the Role(s) of Nox2-containing NADPH Oxidase in the Cerebral Circulation". According to their President Rhian Touyz, it was a ‘fantastic presentation’ that did a lot to remind our friends in the US just what a high standard of research and talented young people we have in Australia. Michael is currently undertaking his doctoral studies at the Department of Pharmacology in Monash University. Michael also visited two laboratories in the US during his visit where he had additional opportunities to present and receive feedback on his doctoral research program. Michael will report on this in the December issue of the e-News.



Corporate Liaison News from Louise Burrell

In the interests of strengthening ties between our sponsors and our members of the High Blood Pressure Research Council of Australia, we are providing an opportunity for the representatives of our sponsors to be better known through an article in HBPRCA eNews. We have asked the representatives of sponsors if they would like to write something about themselves. We had in mind a personal perspective - something perhaps about their position and responsibilities in the company and how they achieved the position, in terms of training and career decisions. We think this information would be of particular interest to our younger members who are facing career decisions themselves and would be interested to hear those from people who have made successful choices along the way.


Our members would also be interested in views on the challenges and exciting developments that you see in the blood pressure field now and over the 5 to 10 years. We have sent out the requests and hope to publish as many of these vignettes as possible before our December Annual Scientific Meeting. The increase in profile will result in greater recognition of the representatives, their company and better interaction around the exhibition stands and other events.

If anyone has misplaced the request, or did not receive an invite but is interested in writing such a personal piece then simply let Prof Geoff Head know by email and he can advise you of the timelines and other details as necessary.


All the very best and many thanks for your ongoing support of HBPRCA.


Sponsor Profiles

JLM Accutek Healthcare – Barbara Iliopoulos

My name is Barbara Iliopoulos, and I am employed by JLM Accutek Healthcare. I am employed as the Business Development Manager for the Diagnostic Cardiology Division, and my responsibilities are very unique and quite diverse.

I am extremely specialized in my role and I am ultimately responsible for the success of the division that I am managing. What does that mean? Imagine that you are running your own business with resources, tools and support in place to enable your success. This is what I am empowered to do within this wonderful organization. I am responsible for business consulting, marketing, product development, recruitment, sales training and coaching, sales forecasting and setting targets, clinical and applications support, customer service, inventory management, building a successful and profitable business unit and making a difference to peoples lives.


My journey has been challenging and extremely rewarding. I have completed a Bachelor of Biomedical Science Degree, a Masters in Business Administration and a Cardiac Technician qualification to ensure that I can support all facets of my role. A burning desire to succeed, a thirst for ongoing learning and personal development and a passion for my chosen field have been the key attributes to my success.


Novartis – Ira Alvarez

Ira Alvarez has been with Novartis since August last year and is the Cardiovascular Senior Product Manager. Her primary focus is the portfolio of anti-hypertensive medicines and ensuring they are accessible to both patients and practitioners, to achieve better health outcomes. Prior to joining Novartis, Ira spent 6 years with Merck Sharpe & Dohme performing roles in various capacities between Sales and Marketing across a range of therapeutic areas including cardiovascular, osteoporosis and respiratory. Before Ira joined the pharmaceutical industry, she spent 6 years helping patients as a physiotherapist, primarily with a sports or spinal injury, both in the public and private setting.


sanofi-aventis australia – Robert Buenaventura

I am a physician by training and was in clinical practice focusing on mental health and psychogeriatrics for about 10 years then I got involved in neuroscience clinical research working with Eli Lilly in Asia starting in 1999. Four years ago I moved to Sydney to work as Associate Medical Director for Asia-Pacific for Covance, a US-based contract research organisation specialising in outsourced clinical trial programs. Last year I joined sanofi-aventis as Senior Medical Manager working in the cardiovascular therapeutic area, which includes hypertension, atrial fibrillation and acute coronary syndromes. My work covers very broad areas that include clinical trials, medical information, pharmacovigilance, and medi-marketing activities.


The main challenge I see with the management of hypertension is patient adherence to an appropriate treatment regime. Patient support programmes (that espouse a healthy lifestyle and improved treatment compliance) and the advent of new therapies in recent years (including fixed-dose combinations) are two key approaches to the patient's success in reaching target blood pressure goal. With major treatment guidelines being planned for revision in the near future, we will see more emphasis on individualised treatment of hypertension and more consideration placed on co-morbid conditions. These show that hypertension management remains to be a very dynamic field.


The photo above was taken during our internal celebration of World Hypertension Day last May. I am located on the left end, wearing glasses and a tie. I'm with the members of our Karvea Brand Team and our special guest for the day, comedian Jono Coleman.



Feature Article: Long-term risk of sustained hypertension in white-coat or masked hypertension

Michele Bombelli, Guido Grassi, Roberto Sega, Giuseppe Mancia, Clinica Medica, Ospedale S Gerardo, University Milan Bicocca, Monza (Milan ), Italy


No conclusive evidence exists as to whether isolated office hypertension or white coat hypertension (WCH) and masked hypertension (MHT), ie the conditions in which, respectively, only office or out-of-office blood pressure (BP) is elevated, are clinically innocent or associated with an increased cardiovascular (CV) risk. 1 This is because in WCH and MHT longitudinal studies have not always documented a greater CV risk2. We addressed this issue using the data of the PAMELA study, by evaluating whether, compared with the “true” normotension, ie the condition in which both office and out-of-office BP are normal, WCH and MHT are associated with an increased rate of development of “sustained” hypertension (SHT), ie the condition in which both office and out-of-office BP are elevated. A peculiar aspect of the study was that out-of-office BP was measured both at home and over 24 hours, which allowed us to obtain 2 separate identifications of WCHT and MHT.



The methods of the PAMELA study has been reported in details elsewhere3. Briefly, 3200 individuals were randomly selected from the white residents of Monza (a town near Milan, Italy), to be representative of its residents for sex, age (25 to 74 years), according to the criteria used by the World Health Organization Monitoring Diseases Project4 conducted in the same geographic area. Data were collected in 2051 subjects (64% of the original sample), and survivors were contacted 10 years later to be re-examined. Between 1990 and 1992, participants were invited to the outpatient sector of the local hospital (Ospedale San Gerardo) in the morning of a working and underwent a number of measurements and collection of information, the ones relevant for the present analysis are as follows: (1) 3 sphygmomanometric BP measurements; (2) a 24-hour (morning-to-morning) ambulatory BP monitoring through a validated oscillometric device (SpaceLabs 90207)  with the BP readings set at 20-minute intervals; (3) 2 home BP measurements (at 7 AM and 7 PM) through a validated semiautomatic device (model HP 5331, Phillips); (4) plasma glucose and lipid profile from venous blood; (5) body mass index (body weight in kilograms divided by the square of the height in meters); (6) information on other CV risk factors, major diseases, and drug treatment. The same data were collected from 2001 to 2002. Care was taken to keep the data collection procedure identical in the 2 occasions. In each individual office, home and 24-hour BP values were averaged separately for the 1990–1992 and 2001–2002 data collection periods. WCHT was diagnosed when, at the first examination, subjects showed an office BP ≥140 mm Hg systolic or 90 mm Hg diastolic with a 24-hour average BP <125 mm Hg and 79 mm Hg diastolic or a home BP <132 mm Hg systolic and 83 mm Hg diastolic. MHT was diagnosed when, at the first examination, office BP was <140 mm Hg systolic and 90 mm Hg diastolic while the 24-hour average values were ≥125 mm Hg or 79 mm Hg diastolic or the home values were ≥132 mm Hg systolic or 83 mm Hg diastolic. The remaining subjects were classified as "true" normotensive or SHT based on normality or elevation, respectively, of either office and ambulatory or office and home BPs. The above-mentioned cutoff ambulatory and home BP values were derived from analysis of the correspondence among the office, ambulatory, and home BP distribution in the PAMELA population5. They closely reflect the cutoff values dividing ambulatory or home HT from normotension indicated by the European guidelines6. The development of SHT was determined by the percentage of subjects with true normotension, WCTH, or MHT at the first examination (1990–1992) who, at the second examination (2001–2002), showed both office and 24-hour or home BP values in the hypertensive range. The {chi}2 test was used to compare the percentage data. The odds ratio of developing SHT was assessed by a logistic regression model, with the true normotensive condition as a reference, and adjusting data for between-group differences in age and sex. A multivariate analysis was used to identify the variables independently predictive of the development of SHT.



Of the 2051 subjects seen at the first examination, 157 died in the subsequent 10 years. A total of 482 subjects refused to participate or could not be selected. Thus, a full set of data was obtained in 1412 subjects, including individuals with SHT at the first examination, which were not considered for further analysis. Entry age, male prevalence, body mass index, serum cholesterol, serum triglycerides and plasma glucose were greater in individuals with WCHT or MHT than in those with true normotension both when these conditions were identified by office versus ambulatory and by office versus home BP. The incidence of new-onset SHT was markedly greater in subjects with WCHT and MHT than in true normotensive individuals both when the groups were identified by office versus ambulatory and by office versus home BP (figure 1).


Fig 1. Mean percentage of individuals SHT based on office/24 hour (top) or office/home (bottom) in subjects with WCHT, MHT, and true normotension (NT) at entry. **P<0.0001 refers to the statistical significance between groups.


Compared with true normotension, the age- and sex-adjusted risks of developing SHT were significantly increased in subjects with WCHT and MHT (OR 2.51, CI 1.79-3.54 for WCHT and 3.81, CI 2.57- 5.64 for MHT, based on office/24 Hour BP; OR 1.78, CI 1.44-2.22 for WCHT and 1.67, CI 1.31-2.12 for MHT, based on Office/Home BP, p< .0001), with no significant difference in the increased risk between these 2 conditions (P=0.372 for office versus ambulatory BP and P=0.398 for office versus home BP). This was also the case when separate calculations were made of the subgroups without any antihypertensive treatment (OR 3.25, CI 2.08-5.07 for WCHT and 3.69, CI 2.17-6.28 for MHT, based on office/24 Hour BP, p<.0001; OR 1.65, CI 1.27-2.15 for WCHT and 1.62, CI 1.20-2.21 for MHT, based on Office/Home BP, p< .005), or those reporting use of antihypertensive drugs at the first or the second examination (WCHT based on office versus 24-hour BP: 1.30, p=0.370; WCHT based on office versus home BP: 2.26, P=0.009; MHT based on office versus 24-hour BP: 1.73, P=0.005; MHT based on office versus home BP: 1.63, P=0.020). Office, home, and 24-hour BP values all independently predicted the development of SHT, together with an independent and usually less important contribution of age and metabolic variables, eg, serum glucose and body mass index. There was, on the other hand, no independent predictive value for use of antihypertensive drugs, lipid profile, smoking habit, and sex in the development of SHT. This was the case also for the presence of 1 or 2 out-of-office BP normalities in WCHT or 1 of 2 out-of-office BP elevations in MHT.



Our study shows that the percentage of subjects who develop SHT over a relatively long time interval (10 years) is greater in individuals who originally had WCHT or MHT than in true normotensive individuals. It further shows that this is the case regardless of whether the definitions of these different BP states are based on office versus ambulatory or on office versus home BP values. The greater choice of new-onset SHT exhibited by WCHT and MHT is by no means marginal, because the age- and sex-adjusted risks were almost doubled and more than tripled when these conditions were diagnosed, respectively, by office versus home and office versus ambulatory BP. Because the incidence of CV fatal and nonfatal events and mortality is greater in the presence of SHT than when only the in-office or out-of-office BP value is increased7 these results provide a strong argument against the clinical "innocence" of these conditions. A number of subjects were on antihypertensive drug treatment, which could have made it more difficult to reach the BP value defining office or out-of-office BP elevation and prevented a precise determination of the "natural" progression to SHT. It should be emphasized, however, that antihypertensive drugs were more likely to be administered in subjects with WCHT or MHT, which means that, if anything, drug treatment might have led to an underestimation of the actual increase in the risk of developing SHT in these 2 conditions. Furthermore, and more importantly, antihypertensive drug treatment was not found to be an independent predictor of new-onset SHT in the multivariate analysis that explored the determinants of this phenomenon. Furthermore, the increment in the risk of developing SHT in WCHT and MHT remained substantially unaltered when calculations excluded subjects reporting an antihypertensive drug assumption, and its size was similar in untreated and treated individuals. The most significant predictors of new-onset SHT were the BP values at entry, an expected finding because it is obvious that the higher the initial BP the greater the chance over the years to reach the cutoff BP value separating normotension from HT. However, this does not entirely explain our results, because the independent determinants of new-onset SHT included metabolic variables.



1.       Messerli FH, Cotiga D. Masked hypertension and white-coat hypertension: therapeutic navigation between scylla and charybdis. J Am Coll Cardiol. 2005; 46: 516–517

2.       Verdecchia P, Angeli F, Gattobigio R, Borgioni C, Castellani C, Sardone M, Reboldi G. The clinical significance of white-coat and masked hypertension. Blood Press Monit. 2007; 12: 387–389

3.       Ambulatory blood pressure normalcy: the PAMELA Study. Cesana G, De Vito G, Ferrario M, Libretti A, Mancia G, Mocarelli P, Sega R, Valagussa F, Zanchetti A. J Hypertens Suppl. 1991 Dec;9(3):S17-23

4.       WHO-MONICA Project Principal Investigators. The World Health Organization Monica Project: a major international collaboration. J Clin Epidemiol. 1998; 41: 105–114

5.       Ambulatory blood pressure normality: results from the PAMELA study. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, Zanchetti A. J Hypertens. 1995 Dec;13(12 Pt 1):1377-90

6.       Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, for the ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187

7.       Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006; 47: 846–853.



Ambulatory Blood Pressure Monitoring (ABPM) Working Group Initiative

Members: Geoff Head, Susie Mihailidou, Karen Duggan, Alexandra Bune, James Sharman, Arduino Mangoni, Peter Howe, Narelle Berry, Diane Cowley, Michael Stowasser, Lawrie Beilin, Jonathan Hodgson, John Chalmers, Carla Morey, Mark Nelson, Mark Brown, Barry McGrath and John Ludbrook


The aim of this working group was to develop a clinical research collaborative to provide sufficient data to derive a robust algorithm, which can link ambulatory blood pressure monitoring (ABPM) (24hr average or awake average) readings to clinic blood pressure (BP). So far we are pleased to have received contributions from 11 research centres from 6 states totally over 8000 subjects with clinical and ambulatory values.  The results from the study have been presented at the European Society of Hypertension meeting in Milan in June.  The main findings were that at each clinic DBP and SBP target, predicted levels of day ABPM were quite similar (within 1 mmHg). This contrasts with the PAMELA study, which showed much lower ABPM values compared to clinic readings, which were measured by doctors. We have now included over 1600 physician measured clinic BP from 4 centres, which gave values much higher than the main data set. The predicted ABPM values closely matched the PAMELA study findings.


We are very pleased to announce that the 17-author manuscript has been finalised and submitted to a journal. We are also pleased to have received endorsement from the National Heart Foundation for this project, and have just received confirmation that our findings will be included in a new revision of the guidelines for ambulatory monitoring. We have also submitted an abstract to the council meeting in December, which compares the differences between physician and trained staff measurements of clinic blood pressure.  


Thank you to everyone who contributed to this project so readily and constructively.



Upcoming Meetings

Cardiology at the Frontier Symposium at VCCRI


We would hereby like to announce the 11th Victor Chang Cardiac Research Institute/St Vincent’s Hospital International Symposium.  Please see the attached flyer and information sheet for further information.  We look forward to seeing you there.

Please forward this email to other interested parties.

To register or for more information please visit the VCCRI website:
http://www.victorchang.edu.au or contact Samantha Strand (02 9295 8610 or 02 9295 8600).

On behalf of the Organising Committee,

Richard Harvey (VCCRI) & Eugene Kotlyar (St. Vincent’s Hospital)


The 23rd Scientific Meeting of the International Society of Hypertension

Recently we sent you information on the 23rd Scientific Meeting of the International Society of Hypertension (ISH 2010) and asked that you make your members aware of this important meeting. We are pleased to announce that the ISH 2010 CALL FOR ABSTRACTS IS NOW OPEN.  We have done this to permit individuals from countries that need a longer time to obtain permission from their institution and/or to obtain a visa to attend the meeting. The deadline for submission is consistent with previous ISH meetings. Complete guidelines, instructions on how to submit an abstract, and topic categories can be found on the ISH 2010 website at www.VancouverHypertension2010.com.  The target audience includes Basic Scientists, Clinicians (Cardiology, Endocrinology, General Medicine, Neurology, Nephrology, Primary Care Physicians, Nurses, and Nutritionists), and Population Health and Public Policy specialists and is inclusive of all individuals interested in cardiovascular health.


8th Asian-Pacific Congress of Hypertension 2011

(8th APCH 2011)

24 - 27 November 2011

Taipei International Convention Center (TICC), Taiwan


Official website has launched! http://www.apch2011.tw/


It is my great honour to share with you the exciting information that the 8th Asian-Pacific Congress of Hypertension 2011 (8th APCH 2011) will be held in Taipei International Convention Center (TICC), from November 24th (Thu) to November 27th (Sun), 2011!


APCH is a rapidly developing and most attractive scientific activity in the Asia-Pacific area and has been held every two years since 1999. It is one of the most important international Hypertension-related events held in this region, which was first gathering in Indonesia (1999), and the participants of 7th APCH 2009 in Malaysia had reached more than 1,600. APCH is authorized by Asian Pacific Society of Hypertension (APSH), which is a confederation of national societies of hypertension, and has been advancing the scientific understanding of hypertension and improving the treatment of hypertension and related vascular disorders in the community. It is a great honour that the Taiwan Hypertension Society is appointed to host the 8th APCH at 2011.


At 8th APCH 2011, in order to attract more physicians’ participation, it’s our great pleasure to announce the Congress will be in conjunction with the Taiwan Society of Internal Medicine and the 3rd World Congress on Ningen Dock together making this EVENT better than ever. Therefore, we are expecting totally more than 7,000 experts around the world, with the majority coming from China, Japan and Korea, will attend the Congress. All the experts are going to share and exchange their advanced knowledge and precious experiences. We believe it will be a marvellous chance to grade up their professional for all our colleagues and friends in the field of Hypertension.


Taking this wonderful opportunity of a world union, we sincerely invite you to join us at the Congress. With your support and participation, we will make this Congress ever more successful!


With open arms and warm regards, we look forward to welcoming to Taipei in November 2011.


Yours truly,


Ming-Fong Chen, MD, PhD

Chairman, 8th Asian-Pacific Congress of Hypertension 2011

President, Taiwan Hypertension Society

President, Taiwan Society of Internal Medicine




HBPRCA would like to acknowledge the support of the following companies:


Corporate members


Corporate Sponsors



Meetings in 2009

World Hypertension Congress 2009 (25th anniversary)

29 October - 1 November 2009
Beijing International Conference Center, China
Click here for meeting website

ASMR 48th National Scientific Conference

15 - 17 November 2009
Hobart, Tasmania
Click here for meeting website




1 – 3 December 2009
Luna Park Sydney
Click here for meeting website

The 2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus

10 - 12 December 2009
Valencia, Spain
Click here for meeting website


Meetings in 2010

Malaysian Society of Hypertension Annual Scientific Meeting

29 – 31 January 2010

Shangri-La Kuala Lumpur

Click here for meeting website

2010 Medical Applications of Synchrotron Research Meeting
15 - 18 February 2010
Melbourne Exhibition Centre
Click here for meeting website

EDDP 2010 – International Conference on Early Disease Detection and Prevention
25 – 28 February 2010

Munich, Germany

Click here for meeting website

6th International Congress of Pathophysiology

22 - 25 September 2010
Click here for meeting website



Meetings in 2011

8th Asian-Pacific Congress of Hypertension 2011

(8th APCH 2011)

24 - 27 November 2011
Taipei International Convention Center (TICC), Taiwan
Click here for meeting website




HBPRCA Secretariat

Athina Patti at Meetings First

4/184 Main Street



Phone +61 3 9739 7697

Fax +61 3 9739 7076

Email hbprca@meetingsfirst.com.au

Web www.hbprca.com.au